Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is ₹239.58. In 2022 the company made an earnings per share (EPS) of ₹182.08 an increase over its 2021 EPS that were of ₹167.03.